Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
19 hedge funds and large institutions have $1.51M invested in Statera Biopharma, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
3% less capital invested
Capital invested by funds: $1.56M → $1.51M (-$54K)
5% less funds holding
Funds holding: 20 → 19 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$68.8K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.25K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1.27K |
| 4 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$945 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$747 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$99.4K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$31K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$16.1K |
| 4 |
BlackRock
New York
|
-$1.71K |
| 5 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $747K | +$68.8K | +24,300 | +13% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $586K | – | – | – |
|
3
Geode Capital Management
Boston,
Massachusetts
| $57K | – | – | – |
|
|
4
BlackRock
New York
| $50K | -$1.71K | -605 | -4% |
|
|
5
Citadel Advisors
Miami,
Florida
| $35K | -$16.1K | -5,686 | -36% |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $13K | +$4.25K | +1,500 | +65% |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $12K | -$99.4K | -35,110 | -91% |
|
|
TDC
8
Thompson Davis & Co
Richmond,
Virginia
| $5K | +$945 | +334 | +33% |
|
|
IA
9
IFP Advisors
Tampa,
Florida
| $2K | -$354 | -125 | -16% |
|
|
WA
10
Winfield Associates
Cleveland,
Ohio
| $2K | – | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| $1K | +$747 | +264 | +264% |
|
|
12
Wells Fargo
San Francisco,
California
| $1K | +$1.27K | +450 | New |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$31K | -10,495 | Closed |
|
|
BFEC
14
Benjamin F. Edwards & Company
St. Louis,
Missouri
| – | -$1K | -500 | Closed |
|
15
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$3 | +1 | New |
|
STAB Hedge Fund Activity: Q3 2017 in Review
19 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2017, worth a combined $1.51M — down 3.5% from $1.56M a quarter earlier.
Fund positioning in STAB was balanced in Q3 2017: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $68.8K. The largest seller was Ladenburg Thalmann Financial Services, cutting an estimated $99.4K.
- 19 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2017, down from 20 in Q2 2017.
- Funds reported $1.51M of Statera Biopharma, Inc. Common Stock stock for Q3 2017, down 3.5% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2017 and 2 closed out, a net change of 0 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2017 was Renaissance Technologies, an estimated $68.8K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q3 2017 was Ladenburg Thalmann Financial Services, an estimated $99.4K sold.
Based on aggregated 13F filings for Q3 2017.